Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on March 18, 2019. The report details a corporate action regarding an existing equity financing arrangement with Oasis Capital, LLC.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed relates to the equity line of credit:
- Original Equity Line: Up to 5,333,333 shares at a fixed price of $0.75 per share.
- Upsize Option: An additional 8,000,000 shares of Common Stock.
- Total Potential Offering: Following the exercise of the Upsize Option, the total number of shares available for purchase under the agreement increased to 13,333,333 shares (excluding the initial 300,000 Commitment Shares).
Material Changes
On March 18, 2019, the Company exercised its "Upsize Option" under the Common Stock Purchase Agreement (CSPA) entered into on January 7, 2019. This action increased the aggregate number of shares the Company may sell to Oasis Capital by 8,000,000 shares. The offering of these additional shares is being made pursuant to the Company's effective shelf registration statement on Form S-3.
Outlook and Management Commentary
The filing confirms the Company's intent to expand its access to capital through the Upsized Equity Line Offering. A separate prospectus supplement for this offering was filed on March 19, 2019. The filing notes that the Company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Verify the terms of the prospectus supplement filed on March 19, 2019, regarding the 8,000,000 additional shares.
- Confirm the current market price of Jaguar Health's Common Stock relative to the $0.75 fixed purchase price.
- Review the Company's cash position to assess the immediate need for capital under this expanded facility.
- Check for any subsequent filings regarding the actual issuance of shares under the upsized line.